Douglas Landy's  Instablog

Douglas Landy
Send Message
Doug Landy is a former sell-side associate, pharmacy director, and pharmacist, with experience that includes investing and stock market analysis since 1995. Doug started his career in healthcare delivering prescriptions for a family owned pharmacy, has 10 years experience in hospital pharmacy,... More
  • Another 'Buy Rating' for the 'Cor'! 0 comments
    Jul 15, 2010 11:56 AM | about stocks: CRMD
    CorMedix Inc. (AMEX:CRMD), a specialty pharmaceutical company that focuses on the licensing and development of therapeutic products for the treatment of cardiac and kidney (cardiorenal) disease, today had a NEW 'BUY' recommendation placed on the stock by National Securities research analyst Jason Kolbert, who states:

    "We see the Company as ideally positioned at the cardio-renal crossroads; that is, treating kidney diseases and rducing the commonly associated cardiovascular and metabolic complications..."  

    This is the second analyst to initiate coverage on the name in recent weeks.

    CorMedix product candidates include a risk-mitigated clinical development profile, target significant niche markets, and have a relatively low cost of development through potential commercialization. Cardiorenal disease includes a broad range of inter-related cardiovascular, kidney and metabolic conditions.

    CorMedix has two Products entering late stage clinical development
    1. Neutrolin for the prevention of central venous catheter (NYSE:CVC) infection and Clotting in hemodialysis (NYSE:HD). The pivotal US study is slated to begin 1H11 with interim data anticipated early in 2012.
    2. Deferiprone for the prevention of contrast induced nephropathy (CIN) in high-risk patients with chronic kidney disease (CKD). Deferiprone (CRMD001) is a novel oral, twice-daily formulation of an iron-binding / chelating drug that was expected that began a Phase 2 study on 6/25/10 with interim data anticipated in 4Q10.

    CorMedix was added to Russell Microcap® Index on 6/29/10.

    CorMedix is gaining attention!! And for good reason.


    Disclosure: No Position
    Stocks: CRMD
Back To Douglas Landy's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.